Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01374438 · ClinicalTrials.gov registry record · Phase 2
3-month Study of MSDC-0160 Effects on Brain Glucose Utilization, Cognition & Safety in Subjects With Alzheimer's Disease
A Phase 2 study, sponsored by Metabolic Solutions Development Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 29
- Enrollment target
NCT01374438 is a Phase 2 study that has completed, run by Metabolic Solutions Development Company. The registered enrollment target is 29 participants.
The verdict
NCT01374438, a Phase 2 study, has completed, sponsored by Metabolic Solutions Development Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 29 participants
- Enrollment target
Study Summary
This study will evaluate the effect of 150 mg MSDC-0160 taken daily for 90 days compared to the effect of placebo on changes in brain glucose utilization using FDG-PET and cognition in older persons with mild Alzheimer's disease. Safety and tolerability of MSDC-0160 in this population will also be studied. These results will be used to design larger studies of MSDC-0160 in persons with mild Alzheimer's disease.
Interventions
- DRUG Placebo
- DRUG MSDC-0160
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2011-07 |
| Est. Completion | 2013-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01374438
The ClinicalTrials.gov registry entry for NCT01374438 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Metabolic Solutions Development Company, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01374438 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01374438 about?
NCT01374438 is a clinical study titled "3-month Study of MSDC-0160 Effects on Brain Glucose Utilization, Cognition & Safety in Subjects With Alzheimer's Disease". This study will evaluate the effect of 150 mg MSDC-0160 taken daily for 90 days compared to the effect of placebo on changes in brain glucose utilization using FDG-PET and cognition in older persons with mild Alzheimer's disease. Safety and tolerability of MSDC-0160 in this population will also be s...
What is the current status of trial NCT01374438?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 29 participants. The study started on 2011-07. Estimated completion is 2013-05.
What interventions are being tested in trial NCT01374438?
The interventions under investigation include: Placebo (DRUG), MSDC-0160 (DRUG).
Who is sponsoring clinical trial NCT01374438?
This trial is sponsored by Metabolic Solutions Development Company, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.